Leonetti, A. http://orcid.org/0000-0001-5415-6703
Verzè, M.
Minari, R. http://orcid.org/0000-0002-4808-0308
Perrone, F.
Gnetti, L.
Bordi, P.
Pluchino, M.
Nizzoli, R.
Azzoni, C.
Bottarelli, L.
Lagrasta, C. A. M.
Mazzaschi, G.
Buti, S.
Gasparro, D.
Cosenza, A.
Ferri, L.
Majori, M.
De Filippo, M.
Ampollini, L.
La Monica, S.
Alfieri, R.
Silini, E. M.
Tiseo, M. http://orcid.org/0000-0002-9204-1728
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG2017-20074)
Article History
Received: 24 February 2023
Revised: 9 October 2023
Accepted: 18 October 2023
First Online: 8 November 2023
Competing interests
: LA received speakers’ fee for Astra-Zeneca, MSD, Roche, Sanofi and Takeda. LA has been on advisory board for BeiGene, Novartis and Sanofi. TM received speakers’ and consultants’ fee from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, Pierre Fabre, Amgen, Merck, Sanofi. TM received institutional research grants from Astra-Zeneca and Boehringer Ingelheim. AR received institutional grants from Astra-Zeneca.
: The study was approved from the Local Ethic Committee on the 11<sup>th</sup> of April, 2018 (Protocol 14033, 09/04/2018). Informed consent was obtained prior to any procedure.